141 related articles for article (PubMed ID: 37941740)
1. Rationale and Methodologic Approach for Assessing Ovarian Cancer Treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.
Ng D; Ross W; Traverso-Ortiz M; Rim SH; Wike JM; Moore AR;
J Registry Manag; 2023; 50(3):85-91. PubMed ID: 37941740
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
Carney ME; Lancaster JM; Ford C; Tsodikov A; Wiggins CL
Gynecol Oncol; 2002 Jan; 84(1):36-42. PubMed ID: 11748973
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.
Eskander RN; Carpenter BA; Wu HG; Wolf JK
Curr Med Res Opin; 2016 Jun; 32(6):1161-5. PubMed ID: 27052730
[TBL] [Abstract][Full Text] [Related]
5. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract][Full Text] [Related]
6. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
8. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
9. Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
Bouchard-Fortier G; Gien LT; Sutradhar R; Chan WC; Krzyzanowska MK; Liu SL; Ferguson SE
Gynecol Oncol; 2022 Mar; 164(3):522-528. PubMed ID: 35063277
[TBL] [Abstract][Full Text] [Related]
10. Effects of access to and treatment in specialist facilities on survival from epithelial ovarian cancer in Australian women: a data linkage study.
Tracey E; Hacker NF; Young J; Armstrong BK
Int J Gynecol Cancer; 2014 Sep; 24(7):1232-40. PubMed ID: 25153678
[TBL] [Abstract][Full Text] [Related]
11. The impact of geographic variations in treatment on outcomes in ovarian cancer.
Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
[TBL] [Abstract][Full Text] [Related]
13. Potential Strategies to Increase Gynecologic Oncologist Treatment for Ovarian Cancer.
Stewart SL; Mezzo JL; Nielsen D; Rim SH; Moore AR; Bhalakia A; House M
J Womens Health (Larchmt); 2021 Jun; 30(6):769-781. PubMed ID: 34128688
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of the data collection process for a multicenter, population-based, case-control design.
Wingo PA; Ory HW; Layde PM; Lee NC
Am J Epidemiol; 1988 Jul; 128(1):206-17. PubMed ID: 3381827
[TBL] [Abstract][Full Text] [Related]
15. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
Dao MD; Alwan LM; Gray HJ; Tamimi HK; Goff BA; Liao JB
Gynecol Oncol; 2013 Aug; 130(2):295-9. PubMed ID: 23632207
[TBL] [Abstract][Full Text] [Related]
16. Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
Salvador S; Scott S; Glanc P; Eiriksson L; Jang JH; Sebastianelli A; Dean E
J Obstet Gynaecol Can; 2020 Aug; 42(8):1021-1029.e3. PubMed ID: 32736853
[TBL] [Abstract][Full Text] [Related]
17. Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival.
Rim SH; Hirsch S; Thomas CC; Brewster WR; Cooney D; Thompson TD; Stewart SL
World J Obstet Gynecol; 2016; 5(2):187-196. PubMed ID: 29520338
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T; Takatori E; Nagasawa T; Kagabu M; Baba T; Shigeto T; Matsumura Y; Shimizu D; Terada Y; Seino M; Ohta T; Nagase S; Shigeta S; Tokunaga H; Shimada M; Kaiho-Sakuma M; Furukawa S; Soeda S; Watanabe T; Takahashi F; Yokoyama Y
Int J Clin Oncol; 2022 Dec; 27(12):1874-1880. PubMed ID: 36214925
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
